Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Abstract excerpt

Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations